Redbiotec’s latest financing round on May 24 2017 was oversubscibed only a few days after emission. The ongoing support by Redbiotec’s investors is an additional proof for Redbiotec’s science and business. With the new funding Redbiotec plans to further optimize its HSV2 vaccine program and to reach a first proof of concept of its COMO program in oncology.